The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for TIB MOLBIOL sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
TIB MOLBIOL is a biotechnology company that designs, manufactures, and supplies reagents and testing kits for diagnostic centers. The company’s product portfolio includes oligonucleotides, testing kits for various, and assays for SNP analysis. It also provides testing kits for Covid-19. The company has operations in the US, Colombia, Australia, Italy, and Spain. TIB Molbiol is headquartered in Eresburgstrasse, Berlin, Germany
The key metrics of TIB MOLBIOL related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As TIB MOLBIOL is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as TIB MOLBIOL.
For a detailed understanding of the performance of TIB MOLBIOL, buy the report here.